As a child growing up in East Millinocket, Maine, Scott MacKenzie was a huge fan of science and science fiction. One of the first magazines he ever subscribed to was Scientific American; one of the first books he ever read was science fiction. Now he can read about the research he has supported as the…
The following interview with Kevin Strange, Ph.D., president of the MDI Biological Laboratory, is excerpted from Eureka, a blog serving the CRO (contract research organization) industry. Launched by Charles River Labs in 2012, the site is a way for scientists to connect and share big ideas on the cutting-edge bench science driving drug discovery and development, particularly in the areas of preclinical safety and assessment, pharmaceutical manufacturing and animal research models.
MDI Biological President Kevin S. Strange, Ph.D., discusses the laboratory's pioneering approach to regenerative medicine in an editorial that originally appeared in the online publication, Regenerative Medicine Network.
The U.S. Patent and Trademark Office has announced that it will grant a patent to MDI Biological Laboratory scientists Voot P. Yin, Ph.D., and Kevin Strange, Ph.D., and their collaborator Michael Zasloff, M.D., Ph.D., for use of the small molecule MSI-1436 to stimulate the repair and regeneration of heart tissue.